EVALUATION OF CARDIAC SAFETY, TOLERABILITY AND EFFICACY OF CUMULATIVE DOSES OF CHF5188 pMDI (FIXED COMBINATION BUDESONIDE/CARMOTEROL 200/1 microg) COMPARED TO SAME CUMULATIVE DOSES OF CARMOTEROL pMDI AND PLACEBO IN ASTHMATIC PATIENTS A MONOCENTER, RANDOMISED, DOUBLE-BLIND, 3-WAY, CROSS-OVER CLINICAL STUDY.

Trial Profile

EVALUATION OF CARDIAC SAFETY, TOLERABILITY AND EFFICACY OF CUMULATIVE DOSES OF CHF5188 pMDI (FIXED COMBINATION BUDESONIDE/CARMOTEROL 200/1 microg) COMPARED TO SAME CUMULATIVE DOSES OF CARMOTEROL pMDI AND PLACEBO IN ASTHMATIC PATIENTS A MONOCENTER, RANDOMISED, DOUBLE-BLIND, 3-WAY, CROSS-OVER CLINICAL STUDY.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2012

At a glance

  • Drugs Budesonide/carmoterol (Primary) ; Carmoterol
  • Indications Asthma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Chiesi Farmaceutici
  • Most Recent Events

    • 09 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top